The facility provides non-dilutive capital and extends runway, reducing near-term equity financing risk. Monitor clinical data readouts for ASPEN-09 (Evorpacept) and ALX2004 safety as triggers for the additional $10M tranche. The floating-rate exposure (Prime or 6% floor) adds interest cost sensitivity.
Price Chart
Executive Summary
ALX Oncology entered into a $50M secured term loan facility with HSBC Ventures, drawing $10M at closing to refinance existing debt with Oxford Finance and Silicon Valley Bank. The facility provides up to $20M in additional committed capital through June 2028 and up to $10M more upon clinical milestones, extending the company's cash runway without equity dilution.
Key Financial Metrics
Key Facts
- Entered into a $50M multi-tranche secured term loan facility with HSBC Ventures USA Inc.
- $10M drawn at closing to refinance existing Oxford/SVB loan; $20M committed available through June 30, 2028.
- Up to $10M additional available upon positive Phase 2 ASPEN-09 (Evorpacept) data and Phase 1 ALX2004 safety data; $10M at lender's sole discretion.
- Term loans mature June 1, 2030; interest at greater of Prime Rate or 6.0% floating; amortization begins July 2028 (or July 2029 if Interest Only Milestone met).
- Secured by substantially all assets with negative pledge on intellectual property; prepayment fees 2% (yr1), 1% (yr2), none thereafter; final payment fee 2% of original principal.
Financial Impact
Up to $50M in debt financing; $10M drawn immediately to refinance existing debt; $20M additional committed; $10M milestone-contingent; $10M discretionary.
Risk Factors
- Debt service costs at floating rate (Prime or 6% floor) could increase if rates rise.
- Secured by substantially all assets; default could trigger acceleration and loss of collateral.
- Clinical trial milestones required for additional $10M tranche; failure to meet them reduces available capital.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-285425 |
| Document: 0001193125-26-285425-index-headers.html | 0001193125-26-285425 |
| Document: 0001193125-26-285425-index.html | 0001193125-26-285425 |
| Document: 0001193125-26-285425.txt | 0001193125-26-285425 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 11d ago | SC 13D/A | $1.14 $1.13 | ▼ −0.88% | ▼ −0.73% | $1.13 (−0.88%) |
Oct 15, 2026 12d ago | 8-K | $1.06 $1.17 | ▲ +10.38% | ▲ +10.81% | $1.13 (+6.60%) |
Sep 28, 2026 29d ago | Press Release | $1.39 $1.21 | ▼ −12.95% | ▼ −14.15% | $1.13 (−18.71%) |
Aug 15, 2026 10w ago | Institutional Cluster | $1.97 $1.99 | ▲ +1.02% | ▲ +2.21% | $1.13 (−42.64%) |
Aug 6, 2026 11w ago | 8-K | $2.11 $1.94 | ▼ −8.06% | ▼ −9.27% | $1.13 (−46.45%) |
Jun 30, 2026 17w ago | 8-K | $2.06 $2.36 | ▲ +14.56% | ▲ +14.30% | $1.13 (−45.15%) |
Jun 26, 2026 17w ago | 8-K | $2.20 $2.19 | ▼ −0.45% | ▼ −1.84% | $1.13 (−48.64%) |
Jun 12, 2026 19w ago | Institutional Cluster | $1.58 $1.53 | ▲ +3.16% | ▲ +3.84% | $1.13 (+28.48%) |
May 8, 2026 24w ago | 8-K | $2.08 $2.04 | ▼ −1.92% | ▼ −3.39% | $1.13 (−45.67%) |
May 8, 2026 24w ago | Press Release | $2.08 $2.04 | ▲ +1.92% | ▲ +3.39% | $1.13 (+45.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers